ArticleFrontiers in microbiology2018
Multidrug Resistant Uropathogenic
Article in Frontiers in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 49 citations in OpenAlex.
- Comparative genomic analyses ofmSystems · 2026Article
- A One Health comparative genomic assessment of antimicrobial-resistantApplied and environmental microbiology · 2026Article
- Human-associated NDM-5-producing multidrug-resistantFrontiers in bioinformatics · 2026Article
- PCR analysis of insertion sequences leads to the generation of artefact amplicons.Access microbiology · 2026Article
- Genomic Diversity and Extended-SpectrumInternational journal of microbiology · 2026Article
- The emergence of highly resistant and hypervirulentEmerging microbes & infections · 2025Article
- ImprovedMicrobial genomics · 2025Article
- Emergence of Carbapenem-Resistant UropathogenicPathogens (Basel, Switzerland) · 2024Article
- ISMicrobiology and molecular biology reviews : MMBR · 2024Review
- Tracking antimicrobial resistance transmission in urban and rural communities in Bangladesh: a One Health study of genomic diversity of ESBL-producing and carbapenem-resistantMicrobiology spectrum · 2024Article
- A systematic review and meta-analysis of carbapenem resistance and its possible treatment options with focus on clinicalHeliyon · 2024Article
- Article
- Molecular epidemiology of extended-spectrum beta-lactamase-producing-Frontiers in microbiology · 2024Article
- Clonal and resistance profiles of fluoroquinolone-resistant uropathogenicFrontiers in microbiology · 2024Article
- Antimicrobial resistance in food-associatedBioscience of microbiota, food and health · 2024Review
- Genetic characterization of plasmid-mediated fluoroquinolone efflux pump QepA among ESBL-producing Escherichia coli isolates in Mexico.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Article
- Emergence and Dissemination of Extraintestinal Pathogenic High-Risk International Clones ofLife (Basel, Switzerland) · 2022Review
- Dissemination of High-Risk ClonesMicroorganisms · 2022Article
- Co-Occurrence of β-Lactam and Aminoglycoside Resistance Determinants among Clinical and Environmental Isolates ofPharmaceuticals (Basel, Switzerland) · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.